RLAY RELAY THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, RELAY THERAPEUTICS INC reported revenue of $350K (down 48.3% from a year earlier), net income of −$83.7M and diluted EPS of −$0.41; over the last four quarters revenue was $10.3M and net income −$286M; for the fiscal year ended December 2025 revenue was $15.4M, up 53.4% on the year before.

RLAY annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $15.4M, gross profit n/a, operating income −$303M, net income −$276M (margin -1800.6%), EPS −$1.61
• Fiscal year ended Dec 2024: revenue $10.0M, gross profit n/a, operating income −$372M, net income −$338M (margin -3374.7%), EPS −$2.36
• Fiscal year ended Dec 2023: revenue $25.5M, gross profit n/a, operating income −$373M, net income −$342M (margin -1338.7%), EPS −$2.79
• Fiscal year ended Dec 2022: revenue $1.38M, gross profit n/a, operating income −$299M, net income −$291M (margin -21036.1%), EPS −$2.59
• Fiscal year ended Dec 2021: revenue $3.03M, gross profit n/a, operating income −$365M, net income −$364M (margin -12012.9%), EPS −$3.82

RLAY quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $350K (down 48.3% year over year), net income −$83.7M, EPS −$0.41
• Quarter ended Mar 31, 2026: revenue $3.00M (down 60.9% year over year), net income −$73.3M, EPS −$0.41
• Quarter ended Dec 31, 2025 (from the annual report): revenue $7.00M, net income −$54.9M, EPS −$0.31
• Quarter ended Sep 30, 2025: revenue $0, net income −$74.1M, EPS −$0.43
• Quarter ended Jun 30, 2025: revenue $677K, net income −$70.4M, EPS −$0.41
• Quarter ended Mar 31, 2025: revenue $7.68M (down 23.3% year over year), net income −$77.1M, EPS −$0.46
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (up 100.0% year over year), net income −$76.0M, EPS −$0.42
• Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$88.1M, EPS −$0.63
• Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$92.2M, EPS −$0.69
• Quarter ended Mar 31, 2024: revenue $10.0M (up 4327.9% year over year), net income −$81.4M, EPS −$0.62
• Quarter ended Dec 31, 2023 (from the annual report): revenue −$1.00K (down 100.4% year over year), net income −$83.5M, EPS −$0.66
• Quarter ended Sep 30, 2023: revenue $25.2M (up 7226.2% year over year), net income −$65.7M, EPS −$0.54
• Quarter ended Jun 30, 2023: revenue $119K (down 67.4% year over year), net income −$98.5M, EPS −$0.81
• Quarter ended Mar 31, 2023: revenue $226K (down 46.1% year over year), net income −$94.2M, EPS −$0.78
• Quarter ended Dec 31, 2022 (from the annual report): revenue $253K (down 55.4% year over year), net income −$67.5M, EPS −$0.55
• Quarter ended Sep 30, 2022: revenue $344K (down 48.3% year over year), net income −$84.2M, EPS −$0.76
• Quarter ended Jun 30, 2022: revenue $365K (down 56.8% year over year), net income −$76.8M, EPS −$0.71
• Quarter ended Mar 31, 2022: revenue $419K (down 56.0% year over year), net income −$62.0M, EPS −$0.57
• Quarter ended Dec 31, 2021 (from the annual report): revenue $567K, net income −$67.5M, EPS −$0.59
• Quarter ended Sep 30, 2021: revenue $666K, net income −$60.8M, EPS −$0.66

RLAY cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$235M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$249M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$300M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$229M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$74.4M, share buybacks n/a

RLAY balance sheet

• Jun 30, 2026: cash $121M, total assets $967M, total liabilities $77.4M, shareholders' equity $890M
• Mar 31, 2026: cash $205M, total assets $700M, total liabilities $57.4M, shareholders' equity $642M
• Dec 31, 2025: cash $84.0M, total assets $621M, total liabilities $54.3M, shareholders' equity $567M
• Sep 30, 2025: cash $91.6M, total assets $670M, total liabilities $62.3M, shareholders' equity $608M
• Jun 30, 2025: cash $114M, total assets $729M, total liabilities $63.2M, shareholders' equity $666M
• Mar 31, 2025: cash $93.5M, total assets $799M, total liabilities $78.3M, shareholders' equity $721M
• Dec 31, 2024: cash $124M, total assets $871M, total liabilities $93.5M, shareholders' equity $778M
• Sep 30, 2024: cash $152M, total assets $930M, total liabilities $91.3M, shareholders' equity $839M

What is RLAY's revenue?

RELAY THERAPEUTICS INC reported $10.3M of revenue over its last four quarters, through June 30, 2026.

Is RLAY profitable?

No. RELAY THERAPEUTICS INC lost $286M over the last four quarters.

What is RLAY's EPS?

Diluted earnings per share over the last four quarters were −$1.56; −$0.41 in the latest quarter.

RLAY ownership and insider trades · All stocks